Jakavi 5mg tablets |Ruxolitinib | MHP

-

                                         JAKAVI 5MG

DESCRIPTION


Jakavi 5mg belongs to the classification of medications called anti-cancer drugs.
Jakavi 5mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 5mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age.
Jakavi 5mg tablet is prescription drug provided under supervision of medical oncologist.
jakavi 5mg tablet
Jakavi 5mg 

MECHANISM OF ACTION

Ruxolitinib is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JAK1 and JAK2 signaling. Patients with MF who either carry the JAK2 V617 mutation or does not have the JAK2 V617F mutation may both respond to Ruxolitinib.

                                                          ADME

Absorption:

Rapid absorption and not affected by food maximum plasma level is 1.5 hours.

Distribution:

Volume of distribution is 76.6 L plasma protein binding is 97%

Metabolism:

metabolized by CYP3A4

Elimination:

Excreted via urine 74% and unchanged drug is <1% and through urine 22%, <1 % as unchanged drug

                                                PRODUCT DETAILS

                                                        Brand : Jakavi
                                                        Ingredients : Ruxolitinib
                                                        Strength : 5mg
                                                        Manufactured : Novartis Ltd
                                                        Package : 60 tablets

DOSAGE MANAGEMENT

Myelofibrosis :

Starting recommended doses for myelofibrosis If Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID
If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID

Polycythemia Vera :

The prescribed dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.

PRECAUTIONS

Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 5mg treatment. If PML is suspected, discontinue Jakavi 5mg tablet and evaluate.
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have resulted in patients administrated with Jakavi 5mg tablet. Do the periodic skin examinations.
Therapy with Jakavi 5mg can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by decreasing the dose or temporarily prohibit Jakavi 5mg tablet. Platelet transfusions may be needed.
Risk of infection occurs by delay initiate treatment with Jakavi 5mg until active serious infection have resolved.
Tuberculosis infection has been resulted in patients administrating Jakavi 5mg tablet. monitor patients getting Jakavi 5mg for signs and symptoms of active tuberculosis and manage promptly.

SIDE EFFECTS

• Cholesterol level increased
• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Decreased RBC
• Reduce in platelet counts
• Nausea & Vomiting
• Sleeplessness
• Liver enzymes increased
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness

CONTACT DETAILS:


EMAIL:          millionhealthpharmaceuticals@gmail.com
PHONE NO: +91-9940472902

Comments

Post a Comment

Popular posts from this blog

Biceltis 440mg | Lapatinib | MHP

-
Image
BICELTIS 440MG DESCRIPTION Biceltis 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Biceltis 440mg helps to decrease the rate of reactivation & mortality. One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication. An FDA approved product Biceltis 440mg which is involved in breast cancer treatment. Biceltis 440mg vial with 858mg of lyophilized powder containing 440mg of Trastuzumab. gastri cancer breast cancer INDICATION The drug Biceltis 440mg injection is used for the treatment of Supportive treatment for breast cancer The drug Biceltis 440mg injection is used for the treatment of Advanced breast cancer The drug Biceltis 440mg injection is used for the treatment of Advanced gastric
Read more

Hermab 440mg injection (Trastuzumab)|Breast cancer treatment|MHP

-
Image
HERMAB 440MG DESCRIPTION Hermab 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Hermab 440mg helps to decrease the rate of reactivation & mortality.. One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication.. An FDA approved product Hermab 440mg injection which is involved in breast cancer treatment. Hermab 440mg vial with 858mg of lyophilized powder containing 440mg of Trastuzumab HERMAB 440mg gastric cancer INDICATION The drug Hermab 440mg is used for the treatment of Supportive treatment for breast cancer The drug Hermab 440mg is used for the treatment of Advanced breast cancer The drug Hermab 440mg is used for the treatment of Advanced gastric cancer MECHANISM OF ACTION Hermab 440
Read more

Tasigna 150mg - Anticancer drugs | view uses, side effects and price | MHP

-
Image
NILOTINIB 150MG DESCRIPTION Nilotinib sold under the brand name Tasigna 150mg tablet and its belongs to targeted cancer cells Tasigna is anticancer drugs, which prohibits development of the cancer cells. Tasigna 150mg  is a prescription medicine, which sold under the supervision of medical oncologist. Tasigna 150mg is also belongs to the class of kinase inhibitors. tasigna 150mg TASIGNA INDICATION Tasigna 150mg tablets is mainly indicated in the conditions like; Chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included Imatinib in adult patients MECHANISM OF ACTION CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene Tasigna 150mg (nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. Tasigna 150mg tablet link to the ATP-bounding site of BCR-ABL protein Tasigna 150mg inhibits proliferation of murine leukemic cell lines and human ce
Read more